Breast cancer screening: A summary of the evidence for the U.S. Preventive Services Task Force

Annals of Internal Medicine

Volumn 137, Issue 5 I, 2002, Pages 347-360

  Humphrey, Linda L ^a   Helfand, Mark ^a   Chan, Benjamin K S ^a   Woolf, Steven H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; BREAST CANCER; BREAST EXAMINATION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; MAMMOGRAPHY; META ANALYSIS; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SELF EXAMINATION; UNITED STATES;

EID: 0037015185     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-137-5_part_1-200209030-00012     Document Type: Review

References (97)

1. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
2. Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study
3. A different perspective on breast cancer risk factors: Some implications of the nonattributable risk
4. Mass screening of asymptomatic women
5. Breast cancer screening
6. Cochrane review on screening for breast cancer with mammography
7. Current methods of the US Preventive Services Task Force: A review of the process
8. Breast cancer
9. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years
10. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years
11. The Gothenburg Breast Cancer Screening Trial: Preliminary results on breast cancer mortality for women aged 39-49
12. Reduced breast cancer mortality in women under age 50: Updated results from the Malmö Mammographic Screening Program
13. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial
14. Followup after 11 years-update of mortality results in the Stockholm mammographic screening trial
15. 14 Years of follow-up from the Edinburgh randomised trial of breast-cancer screening
16. Current results of the breast cancer screening randomized trial: The health insurance plan (HIP) of greater New York study
17. Canadian National Breast Screening Study-2: 13-Year results of a randomized trial in women aged 50-59 years
18. The Canadian National Breast Screening Study: Update on breast cancer mortality
19. The Canadian National Breast Cancer Screening Study-1: Breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years
20. Long-term effects of mammography screening: Updated overview of the Swedish randomised trials
21. The Gothenburg breast screening trial: First results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization
22. Mammographic screening and mortality from breast cancer: The Malmö mammographic screening trial
23. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up
24. Periodic screening for breast cancer: The HIP Randomized Controlled Trial. Health insurance plan
25. The Swedish two county trial of mammographic screening for breast cancer: Recent results and calculation of benefit
26. All-cause mortality in randomized trials of cancer screening
27. Benefits and risks of screening mammography for women in their forties: A statistical appraisal
28. Mammographic screening does not reduce breast cancer mortality
29. Breast cancer screening with mammography: Overview of Swedish randomised trials
30. An overview of the Swedish randomised mammography trials: Total mortality pattern and the representivity of the study cohorts
31. Significant reduction in advanced breast cancer. Results of the first seven years of mammography screening in Kopparberg, Sweden
32. Reduction in mortality from breast cancer after mass screening with mammography
33. Estimating the accuracy of screening mammography: A meta-analysis
34. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: Mammograms and physical examinations
35. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography
36. Effects of estrogen and estrogen-progestin on mammographic parenchymal density
37. Mammographic changes in postmenopausal women on hormonal replacement therapy
38. Effect of age, breast density, and family history on the sensitivity of first screening mammography
39. Likelihood ratios for modern screening mammography. Risk of breast cancer based on age and mammographic interpretation
40. Screening for breast cancer
41. Neglected aspects of false positive findings of mammography in breast cancer screening: Analysis of false positive cases from the Stockholm trial
42. Report of the International Workshop on Screening for Breast Cancer
43. Positive predictive value of screening mammography by age and family history of breast cancer
44. Mammographic screening trials for women aged under 50. A quality assessment and meta-analysis
45. Screening mammography re-evaluated
46. Updated overview of the Swedish Randomized Trials on Breast Cancer Screening with Mammography: Age group 40-49 at randomization
47. Variation in the effectiveness of breast screening by year of follow-up
48. The effectiveness of breast cancer screening by mammography in younger women
49. The quality and interpretation of mammographic screening trials for women ages 40-49
50. Meta-analysis adjusting for compliance: The example of screening for breast cancer
51. Benefit of screening mammography in women aged 40-49: A new meta-analysis of randomized controlled trials
52. Benefit of mammography screening in women ages 40 to 49 years. Current evidence from randomized controlled trials
53. Benefit of mammography screening in women ages 40-49 years: Current evidence from randomized controlled trials
54. Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: Comparison of relative and absolute benefit
55. Screening for breast cancer in women aged under 50: Mode of detection, incidence, fatality, and histology
56. The Swedish randomised mammography screening trials: Analysis of their effect on the breast cancer related excess mortality
57. The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: Should it be done? How?
58. Ten-year risk of false positive screening mammograms and clinical breast examinations
59. Evidence on screening for breast cancer from a randomized trial
60. 16-Year mortality from breast cancer in the UK Trial of Early Detection of Breast Cancer
61. The Canadian National Breast Screening Study: Responses to controversy
62. Screening for cancers of the cervix and breast
63. The role of breast self-examination in early breast cancer detection (results of the 5-years USSR/WHO randomized study in Leningrad)
64. Interim results of a prospective randomized study of self-examination for early detection of breast cancer (Russia/St.Petersburg/WHO)
65. Randomized trial of breast self-examination in Shanghai: Methodology and preliminary results
66. Screening behavior of women after a false-positive mammogram
67. Screening for breast cancer is associated with a low degree of psychological distress
68. Short- and long-term anxiety and depression in women recalled after breast cancer screening
69. Anxiety in a cohort of Swiss women participating in a mammographic screening programme
70. Psychological and behavioral implications of abnormal mammograms
71. The psychosocial consequences of mammography
72. Women with false positive screening mammograms: How do they cope?
73. False positive results do not have a negative effect on reattendance for subsequent breast screening
74. Relationships among breast cancer perceived absolute risk, comparative risk, and worries
75. Effect of false-positive mammograms on interval breast cancer screening in a health maintenance organization
76. US women's attitudes to false positive mammography results and detection of ductal carcinoma in situ: Cross sectional survey
77. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: A dilemma
78. Radiation risk and mammographic screening of women from 40 to 49 years of age: Effect on breast cancer rates and years of life
79. Radiation risk from screening mammography of women aged 40-49 years
80. Incidence of cancer in 161 families affected by ataxia-telangiectasia
81. Efficacy of screening mammography. A meta-analysis
82. Why question screening mammography for women in their forties?
83. Re: Quantitative interpretation of age-specific mortality reductions from the Swedish Breast Cancer-Screening Trials
84. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics
85. An overview of the breast cancer screening controversy
86. The effect of comorbidity on 3-year survival of women with primary breast cancer
87. Continuing screening mammography in women aged 70 to 79 years: Impact on life expectancy and cost-effectiveness
88. What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial
89. Markov models of breast tumor progression: Some age-specific results
90. Sojourn time, sensitivity and positive predictive value of mammography screening for breast cancer in women aged 40-49